MARKET

CCCC

CCCC

C4 Therapeutics, Inc.
NASDAQ
1.820
+0.110
+6.43%
After Hours: 1.801 -0.019 -1.06% 19:39 02/06 EST
OPEN
1.770
PREV CLOSE
1.710
HIGH
1.869
LOW
1.725
VOLUME
829.23K
TURNOVER
--
52 WEEK HIGH
3.720
52 WEEK LOW
1.085
MARKET CAP
176.38M
P/E (TTM)
-1.0892
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CCCC last week (0126-0130)?
Weekly Report · 4d ago
BRIEF-C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule
Reuters · 01/26 21:29
C4 Therapeutics Grants Stock Options to New Employee as Inducement
Reuters · 01/26 21:01
Weekly Report: what happened at CCCC last week (0119-0123)?
Weekly Report · 01/26 10:05
After Hours Most Active for Jan 20, 2026 : NFLX, AAPL, NVDA, T, CCCC, F, PFE, WMT, INTC, GPN, PATH, NUVB
NASDAQ · 01/21 00:59
C4 Therapeutics Unveils Pipeline Strategy Focused on Protein Degraders for Oncology and Inflammatory Diseases
Reuters · 01/20 12:12
Weekly Report: what happened at CCCC last week (0112-0116)?
Weekly Report · 01/19 10:10
Top C4 Therapeutics Executive Makes Notable Move With Company Shares
TipRanks · 01/17 02:01
More
About CCCC
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).

Webull offers C4 Therapeutics Inc stock information, including NASDAQ: CCCC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CCCC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CCCC stock methods without spending real money on the virtual paper trading platform.